The Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitro

Basit Öğe Kaydı
dc.authoridmert, ufuk/0000-0001-8162-5325
dc.authorscopusid55070828100
dc.authorscopusid57932912200
dc.authorscopusid57932853100
dc.authorscopusid57210197087
dc.authorscopusid55665073900
dc.authorscopusid6603630554
dc.authorscopusid23767207200
dc.contributor.authorMert, Ufuk
dc.contributor.authorMuftuoglu, Can
dc.contributor.authorErdem, Sevgi
dc.contributor.authorSadiqova, Aygul
dc.contributor.authorToz, Seray
dc.contributor.authorOzbel, Yusuf
dc.contributor.authorCaner, Ayse
dc.date.accessioned2023-01-12T19:51:03Z
dc.date.available2023-01-12T19:51:03Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPurpose Leishmaniasis is a neglected infectious disease affecting millions of people worldwide. Visceral leishmaniasis (VL), caused by Leishmania infantum and Leishmania donovani, is one of the main clinical forms of the disease and fatal if not treated promptly and properly. Despite being available for the last 70 years, current drugs used in the treatment of leishmaniasis have serious problems as they have high toxicity, require long-term administration and cause serious side-effects, leading to the emergence of resistant and relapse cases. Therefore, there is an urgent need for the discovery of novel antileishmanial molecules and the development of new treatment regimens. The drug used for chemotherapy of B-cell malignancies, Ibrutinib, an inhibitor of Bruton's Tyrosine Kinase (BTK), can offer a new therapeutic perspective due to the functions of BTK on intracellular signaling mechanism of macrophages, which are the primary resident cell for Leishmania. Hence, the study aimed to evaluate ibrutinib as a potential anti-Leishmanial drug. Method In this study, we evaluated the antileishmanial effect of Ibrutinib by in vitroL. infantum infection model using macrophages, with cell viability assay, parasite rescue assay, real-time qPCR. Results We showed that Ibrutinib was significantly more effective than the Glucantime against L. infantum. In addition, our data revealed that Ibrutinib inhibited parasite growth and load without impairing macrophage viability. Conclusions Consequently, due to its efficacy and safety, Ibrutinib may be a promising candidate for the treatment of VL caused by L. infantum as a host-targeted drug.en_US
dc.description.sponsorshipEge University, Scientific Research Projects Coordination [TGA-2019-20180]en_US
dc.description.sponsorshipThis work was supported by Ege University, Scientific Research Projects Coordination (Grant TGA-2019-20180).en_US
dc.identifier.doi10.1007/s11686-022-00630-5
dc.identifier.endpage1739en_US
dc.identifier.issn1230-2821
dc.identifier.issn1896-1851
dc.identifier.issue4en_US
dc.identifier.pmid36260194en_US
dc.identifier.scopus2-s2.0-85140130429en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1732en_US
dc.identifier.urihttps://doi.org/10.1007/s11686-022-00630-5
dc.identifier.urihttps://hdl.handle.net/11454/76212
dc.identifier.volume67en_US
dc.identifier.wosWOS:000870082700001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Int Publ Agen_US
dc.relation.ispartofActa Parasitologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLeishmania infantumen_US
dc.subjectIbrutiniben_US
dc.subjectBTKen_US
dc.subjectMacrophageen_US
dc.subjectBrutons Tyrosine Kinaseen_US
dc.subjectDrug Discoveryen_US
dc.subjectVisceral Leishmaniasisen_US
dc.subjectCellsen_US
dc.titleThe Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitroen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu